StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)
StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock. NASDAQ:AKTX opened at $1.13 on Monday. Akari Therapeutics has a 1-year low of $1.05 and a 1-year high of $2.74. The firm has a fifty day […]